Bat virome

ABT PARTNERS WITH CDC ON NEJM STUDY SHOWING COVID-19 VACCINES EFFECTIVE AT PREVENTING AND MODERATING EFFECTS OF INFECTIONS

Retrieved on: 
Thursday, July 1, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Bat virome, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.

Key Points: 
  • Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.
  • A group of 3,975 healthcare personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 nasal swab testing from December 14, 2020, to April 10, 2021.
  • Such studies increase the publics knowledge and understanding of COVID-19, adds Project Director Danielle Hunt, an Abt vice president and senior epidemiologist.
  • Abt Associates is a global consulting and research firm that uses data and bold thinking to improve the quality of people's lives.

Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections

Retrieved on: 
Tuesday, June 29, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Animal diseases, Infectious diseases, Medical specialties, Pardes Biosciences, FS Development Corp. II (FSII), PARDES BIOSCIENCES, FS DEVELOPMENT CORP. II (FSII)

Pardes Biosciences, Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement.

Key Points: 
  • Pardes Biosciences, Inc., an early-stage biopharmaceutical company, and FS Development Corp. II (Nasdaq: FSII), a special purpose acquisition company sponsored by Foresite Capital, today announced they have entered into a definitive merger agreement.
  • The proposed transaction has been approved by the boards of Pardes Biosciences and FS Development Corp. II, including all of their disinterested directors.
  • Pardes Biosciences is an agile biopharmaceutical company committed to solving some of the worlds most pressing public health challenges.
  • The companys lead product candidate, PBI-0451, is being developed as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections.

PERFORMACIDE® Kills Virus Causing COVID-19 In Just 30 Seconds

Retrieved on: 
Tuesday, June 22, 2021
Sarbecovirus, Respiratory diseases, Animal diseases, Medical specialties, Zoonoses, Bat virome, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Disinfectant

Environmental Protection Agency (EPA)has updated the labeling of PERFORMACIDE Hard Surface Disinfectant to reflect a 30-second contact time to kill SARS-CoV-2, the virus that causes COVID-19, on hard, non-porous surfaces.

Key Points: 
  • Environmental Protection Agency (EPA)has updated the labeling of PERFORMACIDE Hard Surface Disinfectant to reflect a 30-second contact time to kill SARS-CoV-2, the virus that causes COVID-19, on hard, non-porous surfaces.
  • To prove efficacy, PERFORMACIDE was tested directly against the SARS-CoV-2 (COVID-19) virus.
  • CEO and President, Peter Dornau, commented, "Killing the virus that causes COVID-19 in under a minute will dramatically expand the markets for PERFORMACIDE and its sub-registered brands.
  • Mr. Dornau concluded, "PERFORMACIDE already reduces the many steps involved in a full cleaning routine by eliminating rinsing or wiping again.

Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical Trials

Retrieved on: 
Tuesday, June 1, 2021
Sarbecovirus, Zoonoses, Medical specialties, Animal diseases, Bat virome, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome coronavirus 2, Cytopathic effect, Severe acute respiratory syndrome coronavirus, Viral disease

Results from this Phase III trial are expected for objective response rate (ORR) end of Q2 and for progression free survival (PFS) in Q4 2021.

Key Points: 
  • Results from this Phase III trial are expected for objective response rate (ORR) end of Q2 and for progression free survival (PFS) in Q4 2021.
  • In a preclinical experiment using a CPE (cytopathic effect assay), balixafortide demonstrated strong and robust activity against SARS-CoV-2 (COVID-19) infection at clinically relevant concentrations with no adverse cytotoxic effects.
  • In an in vivo hamster animal model, balixafortide showed positive and statistically significant reduction of viral load of SARS COV-2.
  • Balixafortide also reduced COVID19-relevant inflammation markers in the lung including ISG15 gene expression, a key player of respiratory failure in viral infections.

Living History: Our Role in Global Scientific Collaboration for SARS-CoV-2, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, May 27, 2021
Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Infectious diseases, Medical specialties, Animal diseases

It was through science virology, immunology, cellular immunology and the worldwide collaborative effort that a vaccine was approved and made commercially available in 314 days.

Key Points: 
  • It was through science virology, immunology, cellular immunology and the worldwide collaborative effort that a vaccine was approved and made commercially available in 314 days.
  • This webinar will pull back the curtain on partnering with the biopharmaceutical industry for vaccine development as a world class specialty laboratory.
  • For more information, or to register for this event, visit Living History: Our Role in Global Scientific Collaboration for SARS-CoV-2.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.

Sixth Wave Partners with ACAMP to Develop RFID Enabled Virus Detection Products Utilizing AMIPs(TM)

Retrieved on: 
Tuesday, May 25, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Animal diseases, Bat virome, Severe acute respiratory syndrome, COVID-19

SIXW is engaging ACAMP for their expertise in RF technology with the goal of pairing the technology with AMIPs.

Key Points: 
  • SIXW is engaging ACAMP for their expertise in RF technology with the goal of pairing the technology with AMIPs.
  • ACAMP facilities have over 14,000 square feet of lab space and house over $15 million in specialized product development equipment.
  • Offering unparalleled access to world-class engineering expertise, and advanced design, analysis, testing and manufacturing equipment, ACAMP can provide support at every stage of development.
  • AMIPs is a leading-edge detection platform that uses synthetic polymers to swiftly detect viruses such as the SARS-CoV-2 virus that causes COVID-19.

Labcorp Study Suggests COVID-19 Antibodies Remain at Least 10 Months After Infection

Retrieved on: 
Monday, May 24, 2021
MEN, Medical devices, Infectious diseases, Hospitals, Family, Genetics, Consumer, Clinical trials, Cardiology, Diabetes, Biotechnology, AIDS, Health, Women, Pharmaceutical, Seniors, Oncology, Sarbecovirus, Medical specialties, Health, Medicine, Virology, Zoonoses, Bat virome, Peplomer, COVID-19, LabCorp, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

Nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new Labcorp (NYSE: LH) analysis of specimens from 39,086 individuals.

Key Points: 
  • Nearly 87% of naturally infected COVID-19 patients maintained antibodies to SARS-CoV-2 proteins for at least 10 months, according to a new Labcorp (NYSE: LH) analysis of specimens from 39,086 individuals.
  • Our observational analysis provides an encouraging timeline for antibody development and sustainability among the U.S. population, said David Alfego, PhD, Labcorp senior data scientist and the papers lead author.
  • We sincerely hope it sparks more research, helps unearth answers to complex questions and informs critical, post-pandemic planning.
  • Alfego and a team of Labcorp scientists analyzed results from tests used to detect antibodies that guard against spike and nucleocapsid proteins on the SARS-CoV-2 virus.

Meeting Preview: Hot Topics At NUTRITION 2021 LIVE ONLINE

Retrieved on: 
Tuesday, May 18, 2021
Zoonoses, Bat virome, Animal diseases, Health, COVID-19, Occupational safety and health, Public health, Middle East respiratory syndrome–related coronavirus, American Society for Nutrition, Severe acute respiratory syndrome

b'BETHESDA, Md., May 18, 2021 /PRNewswire/ -- Reporters and bloggers are invited to join top nutrition researchers and practitioners for a dynamic virtual program at NUTRITION 2021 LIVE ONLINE .

Key Points: 
  • b'BETHESDA, Md., May 18, 2021 /PRNewswire/ -- Reporters and bloggers are invited to join top nutrition researchers and practitioners for a dynamic virtual program at NUTRITION 2021 LIVE ONLINE .
  • The flagship meeting of the American Society for Nutrition runs June 7-10, 2021 and features research announcements, expert discussions and more.\nExplore the meeting program and register for a press pass to attend .
  • Hundreds of live and recorded sessions will be available on demand for you to enjoy from the comfort of home.\nHighlights from NUTRITION 2021 LIVE ONLINE include:\nCOVID-19, Diet and the Immune System- COVID-19 has remarkably different effects from person to person.
  • In this session, leading researchers take a deep dive into the possible interactions between nutrition, the immune system and the SARS-CoV-2 virus.

ISHLT and JHLT Share COVID-19 Vaccination Findings and Recommendations

Retrieved on: 
Thursday, May 13, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Bat virome, Severe acute respiratory syndrome, Vaccination, Medical specialties, COVID-19 vaccination in the United Kingdom

b'ADDISON, Texas, May 13, 2021 /PRNewswire/ -- Evidence is emerging about the immunogenicity of vaccination to the SARS-CoV-2 virus in immune-suppressed individuals, including organ transplant recipients.

Key Points: 
  • b'ADDISON, Texas, May 13, 2021 /PRNewswire/ -- Evidence is emerging about the immunogenicity of vaccination to the SARS-CoV-2 virus in immune-suppressed individuals, including organ transplant recipients.
  • Vaccination was safe with no evidence of short-term allograft-related adverse effects in either cohort.
  • "We also encourage the continued SARS-CoV-2 vaccination of SOT recipients and priority for vaccination of their household members and caregivers to reduce exposure risk for these vulnerable patients.
  • Importantly, the Journal also serves as a medium of communication of pre-clinical sciences in all these rapidly expanding areas.

Rinsing the Nose with Probiotic Bacteria Reduces Symptoms of COVID-19

Retrieved on: 
Wednesday, May 12, 2021
Medical specialties, Sarbecovirus, Streptococcaceae, Microbiology, Clinical medicine, Bat virome, Bacteriology, Digestive system, Lactococcus, Severe acute respiratory syndrome, Probiotic, COVID-19

b'MONTREAL, May 12, 2021 /PRNewswire/ -A new study suggests that washing the nose twice-daily with probiotic Lactococcus lactis W136 bacteria reduces symptoms in patients infected with SARS-Cov-2, commonly known as COVID-19.

Key Points: 
  • b'MONTREAL, May 12, 2021 /PRNewswire/ -A new study suggests that washing the nose twice-daily with probiotic Lactococcus lactis W136 bacteria reduces symptoms in patients infected with SARS-Cov-2, commonly known as COVID-19.
  • We are therefore very excited to see promising results with what may be prove a new tool against the SARS-Cov-2 pandemic.
  • Single dose sachets of ProbiorinseTMcontain dry powder for reconstitution with water and are stable at room temperature for easy transport and distribution.\nA pre-print of the study is published online on MedRxiv: https://doi.org/10.1101/2021.04.18.21255699 .\nProbionase Therapies is an innovative health sciences company based in Montreal, Canada.
  • Current development focuses on microbiome-based therapeutics for treatment of viral infections of the upper airway ( www.probiorinse.com ) ( www.probiorinse.ca ).\n'